City University of New York (CUNY)

CUNY Academic Works
Publications and Research

Hunter College

2016

A Pretargeted Approach for the Multimodal PET/NIRF Imaging of
Colorectal Cancer
Pierre Adumeau
CUNY Hunter College

Kathryn E. Carnazza
Memorial Sloan Kettering Cancer Center

Christian Brand
Memorial Sloan Kettering Cancer Center

Sean D. Carlin
Memorial Sloan Kettering Cancer Center

Thomas Reiner
Memorial Sloan Kettering Cancer Center

See next page for additional authors

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/hc_pubs/383
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

Authors
Pierre Adumeau, Kathryn E. Carnazza, Christian Brand, Sean D. Carlin, Thomas Reiner, Brian J. Agnew,
Jason S. Lewis, and Brian M. Zeglis

This article is available at CUNY Academic Works: https://academicworks.cuny.edu/hc_pubs/383

Theranostics 2016, Vol. 6, Issue 12

2267

Ivyspring

Theranostics

International Publisher

2016; 6(12): 2267-2277. doi: 10.7150/thno.16744

Research Paper

A Pretargeted Approach for the Multimodal PET/NIRF
Imaging of Colorectal Cancer
Pierre Adumeau1, Kathryn E. Carnazza2, Christian Brand2, Sean D. Carlin2, Thomas Reiner2,3, Brian J.
Agnew4, Jason S. Lewis2,3,5, Brian M. Zeglis1,2,3,6
1.
2.
3.
4.
5.
6.

Department of Chemistry, Hunter College of the City University of New York, New York, NY, 10028;
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065;
Department of Radiology, Weill Cornell Medical College, New York, NY, 10065;
Licensing and Commercial Supply, Thermo Fisher Scientific, Eugene, OR, 97402;
Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY, 10065;
Ph.D. Program in Chemistry, the Graduate Center of the City University of New York, New York, NY, 10016.

 Corresponding author: Phone: 212-896-0443. Fax: 212-772-5332. E-mail: bz102@hunter.cuny.edu.
© Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See
http://ivyspring.com/terms for terms and conditions.

Received: 2016.07.06; Accepted: 2016.09.10; Published: 2016.09.28

Abstract
The complementary nature of positron emission tomography (PET) and near-infrared
fluorescence (NIRF) imaging makes the development of strategies for the multimodal PET/NIRF
imaging of cancer a very enticing prospect. Indeed, in the context of colorectal cancer, a single
multimodal PET/NIRF imaging agent could be used to stage the disease, identify candidates for
surgical intervention, and facilitate the image-guided resection of the disease. While antibodies
have proven to be highly effective vectors for the delivery of radioisotopes and fluorophores to
malignant tissues, the use of radioimmunoconjugates labeled with long-lived nuclides such as 89Zr
poses two important clinical complications: high radiation doses to the patient and the need for
significant lag time between imaging and surgery. In vivo pretargeting strategies that decouple the
targeting vector from the radioactivity at the time of injection have the potential to circumvent
these issues by facilitating the use of positron-emitting radioisotopes with far shorter half-lives.
Here, we report the synthesis, characterization, and in vivo validation of a pretargeted strategy for
the multimodal PET and NIRF imaging of colorectal carcinoma. This approach is based on the rapid
and bioorthogonal ligation between a trans-cyclooctene- and fluorophore-bearing
immunoconjugate of the huA33 antibody (huA33-Dye800-TCO) and a 64Cu-labeled tetrazine
radioligand (64Cu-Tz-SarAr). In vivo imaging experiments in mice bearing A33 antigen-expressing
SW1222 colorectal cancer xenografts clearly demonstrate that this approach enables the
non-invasive visualization of tumors and the image-guided resection of malignant tissue, all at only
a fraction of the radiation dose created by a directly labeled radioimmunoconjugate. Additional in
vivo experiments in peritoneal and patient-derived xenograft models of colorectal carcinoma
reinforce the efficacy of this methodology and underscore its potential as an innovative and useful
clinical tool.
Key words: PET, fluorescence imaging, multimodal imaging, colorectal carcinoma, pretargeting, bioorthogonal
chemistry, site-specific bioconjugation.

Introduction
Colorectal cancer is the second most common
malignancy in women, the third most common
malignancy in men, and the fourth most common
cause of cancer mortality worldwide.1,2 In the US, the

situation is even more dire, as this insidious disease is
the third most common cause of cancer and the
second most common cause of cancer mortality.3 The
surgical excision of the affected segments of the colon
http://www.thno.org
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has emerged as a standard of care for the treatment of
colorectal cancer.4 However, surgery is only effective
in patients with localized disease. Patients with
metastatic disease — who account for up to 25% of
initial diagnoses — are not eligible for resection.5,6 Not
surprisingly, attempts at surgical intervention in these
patients can actually be counter-productive, primarily
because surgery can delay the start of chemotherapy.7
Clearly, the accurate initial staging of colorectal
carcinoma using rapid and non-invasive methods is
absolutely essential to planning effective treatment
regimens.
Over the past two decades, two imaging
modalities have emerged that have begun to have a
transformational impact on the clinical management
of cancer. First, positron emission tomography (PET)
— and immunoPET in particular — has become
established as a powerful tool for the sensitive and
specific functional imaging of cancer.8 Second,
near-infrared fluorescence (NIRF) imaging has proven
to be a very promising technique for the
image-guided resection of tumor tissue, as it
facilitates the real-time, high-resolution delineation of
The
tumor
margins
during
surgery.9,10
complementary nature of these two modalities has led
to a number of preclinical investigations focused on
the creation of immunoconjugates for multimodal
PET and NIRF imaging.11–18 The hypothesis
underpinning this work is that a single multimodal
PET/NIRF imaging agent could perform two valuable
functions. Via PET, the imaging agent could help
clinicians non-invasively determine the extent of
disease and, as a result, whether a given patient is a
candidate for surgery. Then, if surgery does occur, the
same probe could be used for intraoperative NIRF
imaging, thereby aiding surgeons in the delineation of
tumor margins and facilitating the more thorough
resection of the disease. Hong et al., for example, have
recently developed a 89Zr- and IRDye800CW-labeled
immunoconjugate of the CD105-targeting antibody
TCR105 for the multimodal PET and NIRF imaging of
murine models of metastatic breast cancer.15
Despite the immense potential of multimodal
PET/NIRF
immunoconjugates,
two
principal
obstacles stand in the way of their widespread clinical
implementation. Both of these issues stem from the
isotopes traditionally used to radiolabel antibodies.
The multi-day circulation times of antibodies means
that to be effective imaging agents, they must be
labeled with radioisotopes with multi-day physical
half-lives such as 89Zr (t1/2 ~ 3.2 days) or 124I (t1/2 ~ 4.2
days). The use of these long-lived isotopes creates an
important clinical complication: high radiation doses
to healthy organs. In the context of multimodal
PET/NIRF imaging, a second issue arises. In order to
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eschew operations on radioactive patients, multiple
days (or even weeks) would be required between
imaging and surgery to allow the radioisotope to
decay. Critically, it is possible that the cancer can
spread during this delay, rendering the initial staging
scans obsolete and casting the feasibility of surgery
into doubt. The latter point is particularly germane in
the context of malignancies with fast doubling rates,
such as colorectal and ovarian cancer.
In vivo pretargeting
approaches
could
circumvent these issues by harnessing the high
specificity and affinity of radioimmunoconjugates
while simultaneously avoiding their sluggish
pharmacokinetics and high background doses.19 To
achieve this, pretargeting strategies decouple the
antibody from the radioisotope at the time of injection
and combine these two components within the body.
In essence, the radioimmunoconjugate is synthesized
at the tumor itself. In vivo radiolabeling strategies offer
clear advantages over conventional radioimmunoconjugates, as they facilitate tumor imaging at earlier
time points, enable the use of shorter-lived
radionuclides [e.g.64Cu (t1/2 = 12.7 h) and 68Ga (t1/2 = 68
min) rather than 89Zr or 124I], and produce significant
reductions in radiation dose rates to patients. In the
past, several strategies — ranging from bispecific
antibodies to systems based on the affinity between
streptavidin and biotin — have been developed to
facilitate the in vivo ligation of antibodies and
radioligands.19 However, these approaches have
suffered from several drawbacks, including the
immunogenicity of streptavidin-based immuneconjugates and the complexity and lack of versatility
of bispecific antibodies.
Over the past five years, our laboratories and a
handful of others have pioneered in vivo pretargeting
strategies based on the extraordinarily rapid and
bioorthogonal inverse electron demand Diels-Alder
(IEDDA) reaction between tetrazine (Tz) and
trans-cyclooctene (TCO) (Figure 1A).20–27 Generally
speaking, this approach employs two components —
a tetrazine-based radioligand and a TCO-bearing
immunoconjugate — and four facile steps: (1) the
injection of the mAb-TCO conjugate; (2) a localization
time period during which the antibody accumulates
in the tumor and clears from the blood; (3) the
injection of the radiolabeled tetrazine; and (4) the in
vivo click ligation of the two components followed by
the rapid excretion of excess radioligand.23,28
Preclinical PET imaging studies in murine models of
both colorectal and pancreatic cancer have clearly
shown that this pretargeting methodology delivers
high concentrations of radioactivity to tumor tissue at
much earlier time points than directly radiolabeled
antibodies, produces high tumor-to-background
http://www.thno.org
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activity concentration ratios, and significantly reduces
the overall radiation burden to the patient compared
to analogous traditional radioimmunoconjugates.28,29
We contend that a pretargeted approach to
multimodal PET/NIRF imaging would solve both of
the issues that threaten to limit traditional multimodal
radioimmunoconjugates: it would (1) dramatically
lower the radiation dose to healthy tissues and (2)
significantly reduce the requisite lag time between
PET imaging and surgical intervention. To this end,
we have developed a pretargeted multimodal
PET/NIRF
imaging
agent
based
on
an
immunoconjugate of the huA33 antibody labeled with
both a near-IR fluorophore (Dye800) and TCO
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(huA33-Dye800-TCO) and a 64Cu-labeled tetrazine
radioligand (64Cu-Tz-SarAr) (Figs. 1B and 2). We
report that this approach enables the rapid and
non-invasive visualization of tumor tissue with
excellent tumor-to-background activity concentration
ratios. Furthermore, simulated tumor resections using
a NIRF camera clearly demonstrate that this approach
could be a very powerful tool for the real-time
delineation of malignant tissue during image-guided
surgery. Ultimately, we believe that this 64Cu-based
system offers a dramatic improvement over
multimodal PET/NIRF
radioimmunoconjugates
synthesized
using
traditional,
direct-labeling
methodologies.

Figure 1. (A) The inverse electron demand Diels-Alder reaction between tetrazine and trans-cyclooctene; (B) 64Cu-Tz-SarAr.

Figure 2. Biochemical (A) and temporal (B) schematics of the bioorthogonal pretargeting strategy for multimodal PET and NIRF imaging.

http://www.thno.org
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Materials and Methods
A detailed description of experimental
procedures — including synthetic protocols, bioconjugation techniques, radiolabeling methodologies,
and the design and execution of in vitro and in vivo
experiments — can be found in the Supplementary
Materials.

Results and Discussion
Design, Synthesis, and Characterization
The foundation of our multimodal imaging
system lies in the pretargeted approach to the PET
imaging of colorectal cancer that we have previously
reported.27,28 This approach pairs a 64Cu-sarcophagine-based tetrazine radioligand (64Cu-Tz-SarAr)
with a TCO-labeled immunoconjugate of the huA33
antibody (huA33-TCO).28 This antibody has
previously been shown to be an excellent targeting
vector for the A33 antigen, a glycoprotein biomarker
that is over-expressed by 95% of colorectal
carcinomas.30–34 Critically, in vitro studies have shown
that the huA33-A33 antigen complex is not
internalized and persists on the surface of the cell for
days after its formation, making this antibody-antigen
pair an ideal platform for in vivo pretargeting.35 The
near-infrared dye IRDye®800CW (Dye800) was
selected as the fluorescent reporter for this system for
three reasons: it emits tissue-penetrating 789 nm light,
it has been approved for clinical applications, and it
has been successfully employed in several
dual-labeled PET/NIRF immunoconjugates.12,14–17
Two different bioconjugation approaches were
used to append the TCO and Dye800 moieties to the
antibody
in
order
to
achieve
maximum
functionalization with minimal impairment of the
antibody’s functionality. The NIR fluorophore was
attached first. To this end, we employed a
chemoenzymatic strategy that site-specifically
appends cargoes to the biantennary heavy chain
glycans located on the CH2 domains of the antibody’s
Fc region.36 This methodology is designed to mitigate
the adverse effects that the random attachment of
cargoes can have on the immunoreactivity and
pharmacokinetic profile of immunoconjugates.
Indeed, a number of different studies have
demonstrated
that
site-specifically
labeled
immunoconjugates are not only more homogenous
and better-defined than their randomly labeled
cousins but also often boast superior in vivo
performance.36–39 Along these lines, we have
previously applied this bioconjugation strategy to the
development of huA33-based multimodal imaging
agents; however, in this case, we observed that the
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site-specifically modified constructs possess almost
identical — if not slightly more favorable — in vivo
behavior compared to their traditionally synthesized
cousins.18 This result is almost certainly a consequence
of the well-optimized and robust nature of the huA33
antibody. Nonetheless, for the investigation at hand,
we chose to employ this site-specific approach in
order to guarantee that we have minimized the
influence of the bulky and hydrophobic Dye800 on
the in vitro and in vivo performance of the
TCO-decorated antibody.
This site-specific bioconjugation strategy
involves three steps: (1) the removal of the terminal
galactose
residues
of
the
glycans
using
β-1,4-galactosidase;
(2)
the
attachment
of
azide-modified monosaccharides (GalNAz) to the
glycans using Gal-T1(Y289L), a promiscuous
galactosyltransferase; and (3) the ligation of
dibenzocyclooctyne-bearing derivatives of Dye800
(DIBO-Dye800) to the azide-terminated sugar chains
via the strain-promoted azide-alkyne click (SPAAC)
Interestingly,
UV-Vis
ligation
(Fig.
3).40–43
measurements revealed that the huA33-Dye800
immunoconjugate had a degree of labeling of 1.1 ± 0.1
Dye800/mAb. This ratio is admittedly lower than the
theoretical maximum, given that the biantennary
structure of the glycans means that a degree of
labeling of 4 is possible. Indeed, degrees of labeling
closer to 4 have been obtained using chelators (e.g.
DIBO-DFO) and other, shorter-wavelength dyes (e.g.
DIBO-AlexaFluor® 488).18,44 However, this lower
value is consistent with results previously obtained
using a DIBO construct labeled with another bulky
and hydrophobic NIRF dye, AlexaFluorTM 680
(AF680): 1.6 ± 0.2 AF680/mAb.18 Efforts at
understanding this phenomenon are currently
underway, though at present we hypothesize that this
reduction in reaction efficiency may best be explained
by the steric hindrance produced by the introduction
of a bulky and hydrophobic fluorophore with a large
hydrodynamic radius.
The site specificity of this bioconjugation
procedure was demonstrated via denaturing gel
electrophoresis
experiments
performed
on
huA33-Dye800 and huA33-Dye800-TCO (vide infra)
before and after treatment with PNGaseF, an
endoglycosidase known to efficiently cleave the
N-linked oligosaccharides from the CH2 domains.
Importantly, in the lanes containing the untreated
immunoconjugates, fluorescence signal can only be
observed in the band representing the heavy chain.
Even more convincingly, a complete loss of
fluorescence can be observed for the heavy chain
bands of the PNGaseF-treated immunoconjugates
(Fig. S1 and S2).
http://www.thno.org
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Figure 3. Schematic of the synthesis of huA33-Dye800-TCO.

Figure 4. Planar (left) and maximum intensity projection (MIP; right) pretargeted PET images of a nude mouse bearing subcutaneous SW1222 xenograft on the left
shoulder. The mouse was injected with huA33-Dye800-TCO (100 μg; 0.66 nmol), followed 48 h later by 64Cu-Tz-SarAr (350-400 μCi; 0.66-0.77 nmol). The coronal
slices intersect the center of the tumors.

Next, in line with previously reported
procedures, TCO moieties were grafted to the
huA33-Dye800 immunoconjugate through the
coupling of NHS ester-bearing TCOs to the lysine
residues of the antibody. The site-specific conjugation
of TCO via a dual labeling approach similar to that
which we have recently published was considered.18,27
However, we did not want the degree of labeling of
TCO to be impacted by the presence of Dye800 or
limited by the availability of the four azide-modified
monosaccharides. Ultimately, the conjugation of
TCO-NHS to huA33-TCO yielded the completed
huA33-Dye800-TCO conjugate after purification via
size exclusion chromatography.23 Quantification of
the number of active TCO moieties attached to the
antibody was achieved via UV-Vis spectrophotometry
following the reaction of huA33-Dye800-TCO with a
tetrazine-bearing fluorescent probe: Tz-PEG7-AF488.
A degree of labeling of 3.0 ± 0.5 active TCOs/mAb
was obtained. Finally, in order to assess the impact of
the two bioconjugations on the affinity of the antibody
for its target, an antigen binding assay was performed
using A33 antigen-expressing SW1222 human
colorectal carcinoma cells. The 64Cu-labeled
radioimmunoconjugate — obtained via the ex vivo
reaction of huA33-Dye800-TCO and 64Cu-Tz-SarAr
and subsequent size exclusion chromatography —
possessed an immunoreactive fraction of 0.90 ± 0.03.

In Vivo PET Imaging and Biodistribution
The in vivo performance of pretargeted imaging

with huA33-Dye800-TCO and 64Cu-Tz-SarAr was next
evaluated in mice bearing subcutaneous A33
antigen-expressing SW1222 colorectal carcinoma
xenografts. To this end, huA33-Dye800-TCO (100 µg;
0.66 nmol) was administered intravenously to the
tumor-bearing mice followed — after a 48 hour
pretargeting interval — by 64Cu-Tz-SarAr (350-400
µCi; 0.66-0.77 nmol). Previous work by our
laboratories has illustrated that this 48-hour interval
produces
high
tumor-to-background
activity
concentration ratios as well as high absolute activity
concentrations in the tumor tissue itself.28
PET images were collected 4, 12, and 24 h after
the administration of the radioligand (Fig. 4, Fig. S3).
The images acquired at the earliest time point clearly
illustrate that this system is capable of the rapid and
high contrast visualization of tumor tissue. The
images improve with time, with the tumor far and
away the organ with the highest activity
concentration by 12 and 24 h post-injection.
Biodistribution
experiments
mirrored
the
observations made during PET imaging (Table 1). At 1
h post-injection, the activity concentration in the
tumor is 5.6 ± 1.4 %ID/g, a value which grows to 12.8
± 2.2 %ID/g by 24 h. Over the same time period, the
activity in the blood drops from 6.9 ± 2.1 %ID/g to 2.6
± 0.6 %ID/g. By the later time points, all healthy
organs except for the kidneys have activity
concentrations below — and often well below — 1.9
%ID/g. The kidneys were the non-target organs with
the highest activity concentrations (3.9 ± 0.6 %ID/g
http://www.thno.org
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and 2.1 ± 0.2 %ID/g at 1 and 24 h, respectively), a
result of the renal elimination of excess, ‘unclicked’
64Cu-Tz-SarAr radioligand.
Table 1. Biodistribution data for in vivo pretargeting with
huA33-Dye800-TCO and 64Cu-Tz-SarAr.
Blood
Tumor
Heart
Lung
Liver
Spleen
Stomach
Small Intestine
Large Intestine
Kidney
Muscle
Bone

1h
6.9 ± 2.1a
5.6 ± 1.4
2.7 ± 0.8
3.4 ± 1.5
2.7 ± 0.8
1.6 ± 0.7
0.6 ± 0.2
1.0 ± 0.4
0.5 ± 0.2
3.9 ± 0.6
0.5 ± 0.3
0.8 ± 0.3

4h
5.5 ± 0.9
8.0 ± 1.5
2.2 ± 0.5
3.7 ± 0.7
2.6 ± 0.4
1.3 ± 0.4
0.4 ± 0.1
0.6 ± 0.1
0.8 ± 0.2
3.2 ± 0.1
0.5 ± 0.1
0.6 ± 0.1

12 h
5.3 ± 0.5
15.6 ± 1.7
2.1 ± 0.3
3.3 ± 0.2
2.2 ± 0.2
1.3 ± 0.2
0.3 ± 0.1
0.6 ± 0.1
0.4 ± 0.1
2.9± 0.3
0.6 ± 0.1
0.8 ± 0.2

24 h
2.6 ± 0.6
12.8 ± 2.2
1.1 ± 0.2
1.6 ± 0.3
1.9 ± 0.4
1.2 ± 0.3
0.3 ± 0.1
0.5 ± 0.1
0.4 ± 0.2
2.1 ± 0.2
0.3 ± 0.1
0.6 ± 0.1

aValues are %ID/g ± SD. Mice (n = 4) bearing subcutaneous SW1222 xenografts
were administered huA33-Dye800-TCO (100 µg; 0.66 nmol) via tail vein injection.
After 48 h, the same mice were administered 64Cu-Tz-SarAr (300-400 µCi; 0.66-0.77
nmol), also via tail vein injection. Stomach, small intestine, and large intestine
values include contents.

These biodistribution results underscore some
intriguing differences between this multimodal
pretargeting system and our previously published
PET-only pretargeting strategy based on huA33-TCO
and 64Cu-Tz-SarAr.28 In experiments using a 48 h
pretargeting interval, the latter system yielded a
tumoral activity concentration of 4.5 ± 0.4 %ID/g at 1
h post-injection, a value which did not appreciably
change over the course of 24 h (4.9 ± 0.7 %ID/g at 24
h). This strongly suggests that the vast majority of in
vivo click ligations occurred at the tumor rather than
in the blood. In this multimodal pretargeting system,
high activity concentrations (5.6 ± 1.4 %ID/g) can be
observed in the tumor at 1 h post-injection, which is
also indicative of significant click ligations at the
tumor site. However, in this case, the activity
concentrations in the tumor increase over the course of
the experiment, ultimately reaching 12.8 ± 2.2 %ID/g
at 24 h. The activity concentrations in the blood are
also higher for the multimodal approach than the
PET-only strategy: at 4 h post-injection, for example,
the former produces a blood activity concentration of
5.5 ± 0.8 %ID/g compared to a value of 1.8 ± 0.3
%ID/g for the latter. These data suggest that in the
multimodal system, an appreciable amount of
‘in-blood’ ligations are occurring in addition to the
‘on-tumor’ reactions. The most likely explanation for
this phenomenon is that the addition of the
hydrophobic and bulky NIR fluorophore alters the
pharmacokinetics of the immunoconjugate, giving the
huA33-Dye800-TCO construct a longer blood half-life
than its singly modified huA33-TCO cousin.

Ultimately, this issue is not a problem, per se.
However, it does suggest that longer pretargeting
intervals may be necessary to maximize the
dosimetric benefits of this imaging system. Indeed, a
pilot imaging study using a 96 h pretargeting interval
hints that this is the case: the activity concentrations in
the blood are lower throughout the experiment, and
the activity concentration in the tumor are very
similar at 4 and 24 h post-injection (Fig. S4). In the
end, though, it is important to note that even with
these slightly elevated activity concentrations in the
blood, this multimodal pretargeting strategy
produces promising tumor-to-non-target tissue
activity concentration ratios. For example, at 24 h
post-injection,
the
tumor-to-blood
and
tumor-to-muscle activity concentration ratios are ~5
and ~42, respectively (Table S1). Even more
importantly,
the
tumor-to-organ
activity
concentration ratios for the site of primary tumors (the
large intestine) and the most likely site of metastatic
disease (the liver) are also high: ~33 and ~7,
respectively.

In Vivo NIRF Imaging
The PET and biodistribution results strongly
suggest that this system could be highly effective for
the image-guided resection of tumor tissue. To
explore this possibility, NIRF imaging (λex = 745 nm;
λem = 820 nm) was performed on the mice of the PET
imaging
cohort
immediately
before
the
administration of the 64Cu-Tz-SarAr radioligand as
well as 24 and 48 h thereafter (and thus 48, 72, and 96
h after the injection of huA33-Dye800-TCO; see Fig. 2B
for a temporal scheme). The in vivo fluorescence images
clearly illustrate the specific localization of
huA33-Dye800-TCO to the subcutaneous xenografts
(Fig. S5 and Fig. 5A). Simulated tumor resections
further illustrate the potential of this approach for
image-guided surgery. After the removal of the skin
above the fluorescent area, the NIRF signal increases,
and the tumor margins appear clearly, facilitating the
excision of all the tumor tissue (Fig. 5B). NIRF imaging
of the mice after the removal of the tumor clearly
shows that there is no more fluorescent tissue in the
surgical cavity, confirming the complete resection of
the lesion. Finally, the tumors and a selection of 8
organs were excised and compared via ex vivo NIRF
imaging (Fig. 5C). These images and the
accompanying radiant efficiency values reinforce the
specific and selective targeting of this system (Fig. 5D;
for more examples, see Fig. S6-S7). The tumor tissue has
a radiant efficiency of 1393.0 ± 46.0 (units = 106
photons⋅sec-1⋅cm-2⋅sr-1/µW⋅cm-2), a value over an
order of magnitude greater than that of the heart (32.5
± 3.4), lungs (37.0 ± 0.7), liver (107.5 ± 14.0), small
http://www.thno.org
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intestine (54.5 ± 18.4), large intestine (35.9 ± 5.3), and
kidneys (52.0 ± 2.6) (see Table S2). As a result, the
tumor-to-liver radiant efficiency ratio is 13, and the
corresponding ratios for all of the other healthy
organs were >22, including a particularly promising
tumor-to-large intestine radiant efficiency ratio of >38.

Histology and Autoradiography
The subcutaneous xenografts from the mice of
the PET and NIRF imaging cohort were excised in
order to further study the microscopic distribution of
the radioligand and fluorophore (Fig. 6). Staining for
the A33 glycoprotein reveals a clear co-localization
between the expression of the A33 antigen and the
fluorescence of Dye800, which could only be detected
in areas corresponding to tumor cells and not
vasculature, necrosis, or stroma. Most importantly,
autoradiographical analysis reveals that the
radiotracer can only be observed in areas where the
Dye800-fluorescence signal is also detected, providing
further evidence for the in vivo formation of the
64Cu-SarAr-huA33-Dye800 radioimmunoconjugate.
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In Vivo Multimodal Imaging in Alternative
Murine Models of Colorectal Cancer
In order to more fully characterize the in vivo
performance of this multimodal imaging system, we
also performed experiments using peritoneal and
patient-derived colorectal cancer xenografts. With
regard to the former, SW1222 human colorectal
carcinoma cells were injected into the peritoneum of
athymic nude mice. After 3-4 weeks, pretargeted PET
imaging with huA33-Dye800-TCO and 64Cu-Tz-SarAr
clearly revealed small peritoneal tumors while
producing minimal activity concentrations in the
surrounding non-target tissues (Fig. 7A). Subsequent
NIRF imaging confirmed the presence of these lesions
and enabled the image-guided removal of the tumor
tissue (Fig. 7C). Interestingly, in one mouse, the NIRF
imaging revealed the presence of extremely small (<1
mm) colorectal metastases that had escaped detection
via PET, mostly likely due to the higher resolution of
NIRF imaging compared to microPET imaging.

Figure 5. (A) Near-infrared fluorescence images (λex = 745 nm; λem = 820 nm) of a mouse bearing a subcutaneous SW1222 xenograft on the left shoulder acquired
2 h after the injection of huA33-Dye800-TCO and 48 h after the subsequent administration of 64Cu-Tz-SarAr. (B) Simulated image-guided resection of the tumor 96
h after the injection of huA33-Dye800-TCO. From left to right: intact mouse, mouse after removal of the skin (blue arrow) covering the tumor, and mouse after
excision of the tumor (white arrow). (C) Fluorescence imaging of a selection of organs (1: tumor, 2: heart, 3: lungs, 4: liver, 5: spleen, 6: stomach, 7: small intestine,
8: large intestine, 9: kidneys). (D) Ex vivo radiant efficiencies (in 106 photons⋅sec-1⋅cm-2⋅sr1/μW⋅cm-2) of a selection of organs.

http://www.thno.org
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Figure 6. Tumor slices excised from a mouse 72 hours after injection of huA33-Dye800-TCO (100 µg; 0.66 nmol) and 24 h after administration of 64Cu-Tz-SarAr
(350-400 μCi; 0.66-0.77 nmol). Upper section: (A) Hematoxylin and eosin staining, (B) immunofluorescence staining for the A33 antigen, (C) confocal fluorescence
of the Dye800 signal, and (D) digital autoradiography. Lower section: magnified areas of the tumor slices corresponding to the white boxes in the top left panel.

Figure 7. Planar (A) and maximum intensity projection (MIP; B) pretargeted PET images of a nude mouse bearing peritoneal SW1222 tumors (white arrows). The
mouse was injected with huA33-Dye800-TCO (100 µg; 0.66 nmol), followed 48 h later with 64Cu-Tz-SarAr (350-400 μCi; 0.66-0.77 nmol). The coronal slice
intersects the center of the tumors. (C) Simulated NIRF-guided resection of the tumor 96 h after the injection of huA33-Dye800-TCO (and thus 48 h after the
injection of 64Cu-Tz-SarAr; λex = 745 nm and λem = 820 nm). From left to right: NIRF image of the tumors (black arrows) under the skin; NIRF image of the mouse
after the excision of the two tumor masses; inset image of the colon, revealing small tumor lesions visible only via NIRF imaging.

Finally, pretargeted PET/NIRF imaging of mice
bearing patient-derived colorectal cancer xenografts
(PDXs) produced similarly promising results (Fig. 8).
Indeed, both the PET and NIRF image contrast
between the malignant tissue and healthy organs
proved to be more than sufficient for the non-invasive
visualization of the tumor and its efficient
image-guided resection. Interestingly, however, the
tumor-to-blood activity concentration ratios seemed
to be quite a bit higher in these experiments than in
those using SW1222-based xenografts. The most likely
explanation for this phenomenon is that while the
same amount of Dye800-huA33-TCO (100 µg) was

injected for the imaging experiments in both models,
the PDXs do not express the A33 antigen at levels
comparable to their SW1222 xenograft counterparts.
This would naturally result in decreased amounts of
Dye800-huA33-TCO in the tumor, increased amounts
of Dye800-huA33-TCO in the blood, and a higher
proportion of in vivo click ligations with
64Cu-Tz-SarAr that occurs in the blood.

Dosimetry
Finally, the biodistribution data from the
experiments using subcutaneous SW1222 xenografts
were used to perform dosimetry calculations to probe
http://www.thno.org
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the dosimetric benefits of pretargeting with
huA33-Dye800-TCO and 64Cu-Tz-SarAr (see Table S3).
These calculations reveal that the total effective dose
for this multimodal pretargeting strategy is 0.021
mSv/MBq, an over 20-fold reduction compared to
that created by the most clinically relevant alternative:
huA33 directly labeled with 89Zr (89Zr-DFO-huA33;
0.416 mSv/MBq).23 This dosimetric advantage grows
when considering particularly radiosensitive organs
such as the red marrow (40-fold difference),
osteogenic cells (30-fold difference), and kidneys
(33-fold difference). Admittedly — and not
surprisingly, given our previous discussion of the
biodistribution data — this multimodal strategy has a
slightly higher effective dose (0.021 mSv/MBq) than
our PET-only system (0.012 mSv/MBq), most likely
due to the increased activity concentrations in the
blood.

Conclusion
In the preceding pages, we have presented the
development and in vivo validation of a pretargeted
approach to the multimodal PET/NIRF imaging of
colorectal carcinoma. In subcutaneous, peritoneal,
and patient-derived xenograft models, we have
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shown that this technology enables both the
non-invasive visualization of malignant lesions and
the NIRF-guided excision of tumor tissue. As a result,
we contend that this technology could offer an
effective alternative to multimodal imaging with
directly radiolabeled antibodies that lowers the total
effective radiation dose to patients and reduces the lag
time between PET imaging and surgery. Moving
forward, we plan on pursuing three different avenues
for the optimization of this approach: (1) the use of
longer pretargeting intervals (e.g. 96 or 120 h) that will
reduce the amount of immunoconjugate remaining in
the blood at the injection of the radioligand; (2) the
use of tetrazine-bearing clearing agents to remove
residual immunoconjugate in the blood after the
pretargeting interval; and (3) the use of radioligands
bearing even shorter-lived radioisotopes such as 68Ga
(t1/2 = 68 min) and 18F (t1/2 = 110 min).21,26,45,46 We
believe that each of these steps could improve upon
the already significant advantages that this system
provides
over
imaging
with
traditional
radioimmunoconjugates. Indeed, all three alterations
could lead to additional reductions in the effective
radiation dose created by this system, and the third
could further reduce the necessary interval between

Figure 8. Planar (A) and maximum intensity projection (MIP; B) pretargeted PET images of a nude mouse bearing a patient-derived colorectal carcinoma xenograft
(T: tumor, L: liver, H: heart). The mouse was injected with huA33-Dye800-TCO (100 µg; 0.66 nmol), followed 48 h later with 64Cu-Tz-SarAr (350-400 μCi; 0.66-0.77
nmol). The coronal slices intersect the center of the tumor. (C) Simulated image-guided resection of the tumor 96 h after the injection of huA33-Dye800-TCO (and
thus 48 h after the administration of 64Cu-Tz-SarAr). From left to right: intact mouse, mouse after removal of the skin (blue arrow) covering the tumor, and mouse
after excision of the tumor (white arrow).
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PET and surgery. Along these lines, we are currently
working to develop pretargeted PET/NIRF imaging
systems that leverage the Al18F-labeled tetrazine
radioligands that our laboratories have recently
reported as well as a series of novel 68Ga-labeled
tetrazines. Ultimately, it is our sincere hope that this
new multimodal imaging technology will have a
significant impact on both the staging and surgical
intervention of patients with colorectal carcinoma.

Supplementary Material
Supplementary tables and figures.
http://www.thno.org/v06p2267s1.pdf
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